Real-World, First-Line Osimertinib Treatment in Epidermal Growth Factor Receptor Mutation-Positive (EGFRm) Advanced NSCLC

被引：0
|
作者：
Nieva, J. [1 ]
Griesinger, F. [2 ]
Kim, Y. [3 ]
Cohen, A. [4 ,5 ]
Horvat, P. [6 ]
Lu, S. [7 ]
Taylor, A. [8 ]
Yu, N. [8 ]
Sawyer, W. [8 ]
Shenolikar, R. [8 ]
Shaw, S. [8 ]
机构：
[1] Univ Southern Calif, Norris Canc Ctr, Los Angeles, CA 90007 USA
[2] Pius Hosp Oldenburg, D-26121 Oldenburg, Germany
[3] Kyoto Univ, Grad Sch Med, Kyoto, Japan
[4] Flatiron Hlth Inc, New York, NY 10013 USA
[5] NYU, Sch Med, New York, NY USA
[6] Iqvia, Real World Solut, Emea Data Sci Hub, London, England
[7] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[8] Astrazeneca, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
osimertinib; non-small cell lung cancer; Real-world evidence;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.66
引用
收藏
页码：S616 / S617
页数：2
相关论文
共 50 条
  • [41] Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)
    Vishwanathan, Karthick
    Dunyak, James
    Overend, Philip
    Hartmaier, Ryan
    Markovets, Aleksandra
    Chmielecki, Juliann
    Mugundu, Ganesh
    Barrett, Carl
    Tomkinson, Helen
    Johnson, Martin
    CANCER RESEARCH, 2020, 80 (16)
  • [42] Afatinib in EGFR Mutation-Positive (EGFRm plus ) NSCLC Harbouring Uncommon Mutations: Experience in 'Real-World' Clinical Practice
    Brueckl, W.
    Laack, E.
    Hoffmann, C.
    Zhou, C.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S670 - S671
  • [43] Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer
    Hirata, Tsuyoshi
    Watanabe, Kageaki
    Hosomi, Yukio
    Yoh, Kiyotaka
    Usui, Kazuhiro
    Kishi, Kazuma
    Naka, Go
    Tamano, Shu
    Uemura, Kohei
    Kunitoh, Hideo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (03) : 269 - 274
  • [44] Characteristics of Real-World Study: Taking the Observational Study of Osimertinib in Patients with EGRF Mutation-Positive NSCLC as an Example
    Feng, Rui-hua
    Cheng, Jiu
    Guo, Min-jiang
    Jiang, Xiao-tong
    Zhang, Chi
    LI, Ya-zi
    LATIN AMERICAN JOURNAL OF PHARMACY, 2023, 42 (05): : 1034 - 1041
  • [45] Real-World Effectiveness of EGFR TKI First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in US
    Gautam, S.
    Herms, L.
    Bartolome, L.
    Pastel, M.
    Wilner, K.
    Fisher, M.
    Ivanova, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S618 - S619
  • [46] START: Real-world Prospective Study on Sequential Therapy with First-Line Afatinib in Chinese Patients with EGFRm plus Advanced NSCLC
    Zhou, J.
    Xue, Z.
    Li, Q.
    Ling, X.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S632 - S633
  • [47] Durvalumab plus chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis
    Cho, B. C.
    Ahn, M. J.
    Baik, C.
    Garcia, R.
    Goldman, J. W.
    Kim, S-W.
    Lee, J. S.
    Nishio, M.
    Ponce, S.
    Salgia, R.
    Teraoka, S.
    Yoshida, T.
    Yu, H. A.
    Ambrose, H.
    Cosaert, J.
    Hartmaier, R.
    Maidment, J.
    Pluta, M.
    Okamoto, I.
    ANNALS OF ONCOLOGY, 2022, 33 : S34 - S35
  • [48] Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
    Chang, Gee-Chen
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Chao, Heng-Sheng
    Yang, Cheng-Ta
    Lin, Chien-Chung
    Hung, Jen-Yu
    Hsiao, Sheng-Yen
    Wang, Chin-Chou
    Chian, Chih-Feng
    Hsia, Te-Chun
    Chen, Yuh-Min
    PLOS ONE, 2024, 19 (05):
  • [49] Epidermal growth factor receptor mutation (EGFRm) testing in advanced non-small cell lung cancer (aNSCLC) in a real-world setting
    Subramanian, J.
    Gregg, J.
    Wang, H.
    Sun, P.
    Yu, B.
    Shenolikar, R.
    Chau, M.
    Taylor, A.
    Leighl, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S888 - S889
  • [50] Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer
    Lee, Jang Ho
    Kim, Eun Young
    Park, Cheol-Kyu
    Lee, Shin Yup
    Lee, Min Ki
    Yoon, Seong-Hoon
    Lee, Jeong Eun
    Lee, Sang Hoon
    Kim, Seung Joon
    Lee, Sung Yong
    Lim, Jun Hyeok
    Jang, Tae -Won
    Jang, Seung Hun
    Lee, Kye Young
    Lee, Seung Hyeun
    Yang, Sei Hoon
    Park, Dong Won
    Park, Chan Kwon
    Kang, Hye Seon
    Yeo, Chang Dong
    Choi, Chang-Min
    Lee, Jae Cheol
    CANCER RESEARCH AND TREATMENT, 2023, 55 (01): : 112 - 122
12345